{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:18Z","timestamp":1790085618899,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875510"],"award-info":[{"award-number":["875510"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["818170"],"award-info":[{"award-number":["818170"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["Epi4MS"],"award-info":[{"award-number":["Epi4MS"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011727","name":"Stockholm l\u00e4ns landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011889","name":"Diamond Light Source","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Kungliga Tekniska H\u00f6gskolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119873","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:40:15Z","timestamp":1788561615000},"page":"119873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-throughput primary B cell cytokines assay for drug screening in multiple sclerosis"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4480-6095","authenticated-orcid":false,"given":"Ming-Mei","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-5505","authenticated-orcid":false,"given":"Nicolas","family":"Ruffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Ortlieb","family":"Guerreiro-Cacais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara Asplund","family":"H\u00f6gelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez Al","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Jagodic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119873_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","article-title":"Neuromodulation by the immune system: a focus on cytokines","volume":"21","author":"Salvador","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine production by human B cells: role in health and autoimmune disease","volume":"210","author":"de Gruijter","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib11","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2026.119873_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/acn3.51965","article-title":"Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets","volume":"11","author":"Feige","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119873_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib16","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119873_bib17","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adk0865","article-title":"Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis","volume":"9","author":"Li","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib20","article-title":"Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay","author":"Sundstr\u00f6m","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.biopha.2026.119873_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.685718","article-title":"High-Throughput Detection of Autoantigen-Specific B Cells Among Distinct Functional Subsets in Autoimmune Donors","volume":"12","author":"Joosse","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334720","article-title":"Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis","volume":"15","author":"Marti","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","article-title":"BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy","volume":"143","author":"Li","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2026.119873_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/2472555220954389","article-title":"Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery","volume":"25","author":"Platchek","year":"2020","journal-title":"SLAS Discov."},{"key":"10.1016\/j.biopha.2026.119873_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in Inflammatory Disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119873_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B Cells Activate Brain-Homing, Autoreactive CD4(+) T Cells in Multiple Sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119873_bib27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.25508","article-title":"Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis","volume":"86","author":"van Langelaar","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib29","first-page":"626","article-title":"Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis","volume":"6","author":"Li","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119873_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119873_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081338","article-title":"Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions","volume":"11","author":"Szklener","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119873_bib32","unstructured":"J C. Statistical power analysis for the behavioral sciences. 1988."},{"key":"10.1016\/j.biopha.2026.119873_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41587-020-00790-7","article-title":"BTK blockers make headway in multiple sclerosis","volume":"39","author":"Dolgin","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119873_bib34","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","article-title":"Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study","volume":"5","author":"Conaghan","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.biopha.2026.119873_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177747","article-title":"Next generation Bruton's tyrosine kinase inhibitors - characterization of in vitro potency and selectivity","volume":"1002","author":"Pulz","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119873_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R. D."},{"key":"10.1016\/j.biopha.2026.119873_bib37","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development","volume":"61","author":"Crawford","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119873_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119873_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71750-z","article-title":"Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow)","volume":"10","author":"Rezk","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119873_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5281823","article-title":"Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines","volume":"2016","author":"Van Belle","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.biopha.2026.119873_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/WCO.0000000000001363","article-title":"Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success","volume":"38","author":"Cree","year":"2025","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib44","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2026.119873_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:06:28Z","timestamp":1790082388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"alternative-id":["S0753332226009091"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119873","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput primary B cell cytokines assay for drug screening in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119873"}}